Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 14Head & Neck 2CNS 2Thoracic 1Sarcoma 1Other solid neoplasm 1Other 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5760Lung Neoplasms 3725Small Cell Lung Carcinoma 1021Breast Neoplasms 668Neoplasms 615Colorectal Neoplasms 562Melanoma 479Ovarian Neoplasms 435Neoplasm Metastasis 432Pancreatic Neoplasms 387Stomach Neoplasms 332Carcinoma, Renal Cell 312Adenocarcinoma of Lung 309Squamous Cell Carcinoma of Head and Neck 306Head and Neck Neoplasms 295Prostatic Neoplasms 285Mesothelioma, Malignant 281Esophageal Neoplasms 266Mesothelioma 244Colonic Neoplasms 226Brain Neoplasms 217Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 212Uterine Cervical Neoplasms 209Endometrial Neoplasms 175Sarcoma 172Carcinoma, Hepatocellular 159NSCLC 136Carcinoma 128Kidney Neoplasms 127

Interventions

LY2940680 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pituitary Diseases × Thoracic × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡